Physician profile
Divya Akella
NPI 1700260726
$1,420.43
in general payments reported to CMS, 2019-2025
18 companies · $848 in 2025
The $848 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $11.41 · 2022: $72.19 · 2023: $77.31 · 2024: $311 · 2025: $848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,234 · Education: $1.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,234.31 |
| Education | $1.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $242.10 | 2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $222.69 | 2024-2025 | Jynarque |
| Vantive US Healthcare LLC | $152.99 | 2025 | Renal - Acute |
| Ardelyx, INC. | $86.71 | 2024-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $80.80 | 2019-2024 | Recarbrio, Zerbaxa, Dificid |
| Pfizer INC. | $76.56 | 2019-2024 | |
| Glaxosmithkline, LLC. | $72.98 | 2024-2025 | Benlysta |
| Alexion Pharmaceuticals, INC. | $61.58 | 2024-2025 | Ultomiris |
| Aurinia Pharma U.S., INC. | $61.32 | 2024-2025 | Lupkynis |
| Janssen Pharmaceuticals, INC | $57.76 | 2019-2020 | |
| Calliditas Therapeutics US INC. | $57.60 | 2024-2025 | Tarpeyo |
| Melinta Therapeutics, LLC | $50.86 | 2019-2023 | Kimyrsa, Vabomere |
| Vifor Pharma, INC. | $44.87 | 2024-2025 | Veltassa |
| Astrazeneca Pharmaceuticals Lp | $44.73 | 2024-2025 | Farxiga |
| Mylan Specialty L.P. | $35.46 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $30.66 | 2024 | Rebyota |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.00 | 2024 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $15.76 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Divya Akella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.